Cangrelor is available as a lyophilized powder in single-use vials containing 50 mg of cangrelor as the tetrasodium salt.3023 Each vial also contains mannitol, sorbitol, and sodium hydroxide to adjust the pH.3023
Each 50-mg vial of cangrelor should be reconstituted with 5 mL of sterile water for injection.3023 The vial should be gently swirled until all of the powder has fully dissolved; vigorous mixing should be avoided.3023 Any foam that forms should be allowed to settle.3023 The reconstituted solution should be visually inspected for particulate matter.3023
The reconstituted solution must be diluted prior to administration.3023 The entire contents of the vial should be withdrawn and diluted in an infusion bag containing 250 mL of sodium chloride 0.9% or dextrose 5% to yield a solution containing cangrelor 200 mcg/mL.3023 The solution should be thoroughly mixed.3023
Trade Name(s)
Kengreal
Cangrelor tetrasodium is administered by rapid intravenous injection of a bolus dose followed by continuous intravenous infusion via a dedicated line.3023 The bolus dose should be withdrawn from the bag containing the diluted drug and administered (by manual intravenous push or by pump) over less than 1 minute.3023 The continuous intravenous infusion should immediately follow administration of the bolus.3023
Intact vials of cangrelor tetrasodium should be stored at controlled room temperature.3023 Cangrelor tetrasodium is a white to off-white lyophilized powder that forms a clear, colorless to pale yellow solution when reconstituted with sterile water for injection.3023
The manufacturer states that the reconstituted solution should be diluted immediately.3023 The drug is noted to be stable for up to 12 hours at room temperature when diluted in dextrose 5% or up to 24 hours at room temperature if diluted in sodium chloride 0.9%.3023 Any unused portion should be discarded.3023
For a list of references cited in the text of this monograph, search the monograph titled References.